"Carcinoembryonic Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
| Descriptor ID |
D002272
|
| MeSH Number(s) |
D12.776.395.550.200.210 D12.776.543.550.200.210 D23.050.285.329 D23.050.301.350.210 D23.101.140.300
|
| Concept/Terms |
Carcinoembryonic Antigen- Carcinoembryonic Antigen
- Antigen, Carcinoembryonic
- CD66e Antigen
- Antigens, CD66e
- CD66e Antigens
- Antigen, CD66e
|
Below are MeSH descriptors whose meaning is more general than "Carcinoembryonic Antigen".
Below are MeSH descriptors whose meaning is more specific than "Carcinoembryonic Antigen".
This graph shows the total number of publications written about "Carcinoembryonic Antigen" by people in this website by year, and whether "Carcinoembryonic Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2004 | 0 | 3 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles.
-
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer. JAMA Netw Open. 2023 11 01; 6(11):e2343512.
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
-
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
-
Necessity of posttreatment surveillance for low-grade appendiceal mucinous neoplasms. J Surg Oncol. 2021 Dec; 124(7):1115-1120.
-
Adherence to postresection colorectal cancer surveillance at National Cancer Institute-designated Comprehensive Cancer Centers. Cancer Med. 2018 11; 7(11):5351-5358.
-
A cross-sectional study of tumor markers during normal and high-risk pregnancies. Int J Gynaecol Obstet. 2015 Jun; 129(3):203-6.
-
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw. 2014 Jun; 12(6):907-13.
-
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
-
Endosonographic and cyst fluid characteristics of cystic pancreatic neuroendocrine tumours: a multicentre case series. Dig Liver Dis. 2013 Sep; 45(9):750-3.
-
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012 Aug; 19(8):2471-6.